会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 62. 发明申请
    • Prodrugs via acylation with cinnamate
    • 前药与肉桂酸酯通过酰化
    • US20020187992A1
    • 2002-12-12
    • US10066306
    • 2002-01-31
    • Carl W. GilbertEleanor B. McGowanKirby S. BlackT. Gregory P. Harper
    • A61K031/435A61K031/277A61K031/216C07D213/55
    • C07D207/416C07D207/452C07D207/46C07D231/12C07D233/56C07D249/08C07D295/096C07D305/14C07D405/12C07D491/04C07D491/22C07H15/252
    • A prodrug composition containing a cinnamate moiety and a biologically active molecule moiety which can be released by hydrolysis or activated by light is disclosed. The cinnamate moiety can have substituents of various electronically donating or electronically withdrawing groups to modify the cinnamate moiety's electric properties as well as photo reactivities for the purpose of achieving a proper hydrolysis rate of the acyl bond between the biologically active molecule moiety and the cinnamic acid backbone. The biologically active molecule can be any biologically active agent or diagnostic, for example, a chemotherapeutic such as a paclitaxel, campotothecin, doxorubicin, amethopterin, etoposide, or fluconazole. The prodrug composition can be modified to add a carrier moiety on the prodrug composition for targeting or to facilitate uptake of the drug. The prodrug compositions can be activated with an energy source to release the drug at the desired site. Representative energy sources can be in the form of electric force, ultrasound, light or radiation of a radioactive material which can be administered either externally or internally.
    • 公开了含有肉桂酸酯部分和可通过水解释放或被光活化的生物活性分子部分的前药组合物。 肉桂酸酯部分可以具有各种电子供体或电子取代基团的取代基,以改变肉桂酸酯部分的电性能以及光反应性,以实现生物活性分子部分和肉桂酸骨架之间的酰基键的适当水解速率 。 生物活性分子可以是任何生物活性剂或诊断剂,例如化学治疗剂,例如紫杉醇,喜树碱,多柔比星,灭草灵,依托泊苷或氟康唑。 可以修饰前药组合物以在前药组合物上加入载体部分以靶向或促进药物摄取。 前药组合物可以用能量源活化以在期望的位置释放药物。 代表性的能源可以是放射性物质的电力,超声,光或辐射的形式,其可以在外部或内部施用。
    • 67. 发明授权
    • Phenyldiboronic acid reagents and complexes
    • 苯二硼酸试剂和络合物
    • US6124471A
    • 2000-09-26
    • US407673
    • 1999-09-28
    • Mark L. StolowitzEdward A. KesickiKevin P. LundKarin A. Hughes
    • Mark L. StolowitzEdward A. KesickiKevin P. LundKarin A. Hughes
    • C07C229/38C07C233/49C07C233/51C07C237/12C07C237/22C07C255/13C07C259/10C07C271/22C07C281/02C07D207/44C07D207/452C07D207/46C07D213/71C07F5/02G01N33/531G01N33/543
    • C07C233/49C07C229/38C07C233/51C07C237/12C07C237/22C07C255/13C07C259/10C07C271/22C07C281/02C07D207/452C07D207/46C07D213/71C07F5/025C07K5/0207G01N33/531G01N33/54353Y10S530/81Y10S530/816
    • Reagents suitable for the modification of a bioactive species for the purpose of incorporating one or more phenyldiboronic acid (PDBA) moieties for subsequent conjugation to a different (or the same) bioactive species having one or more pendant boronic compound complexing moieties of the general formula of General Formula I, ##STR1## wherein group R is a reactive electrophilic or nucleophilic moiety suitable for reaction of the PDBA reagent with a bioactive species. Group Z is a spacer selected from a saturated or unsaturated chain up to about 0 to 6 carbon equivalents in length, an unbranched saturated or unsaturated chain of from about 6 to 18 carbon equivalents in length with at least one intermediate amide or disulfide moiety, and a polyethylene glycol chain of from about 3 to 12 carbon equivalents in length. Group Q is a linkage that includes one of amide, ether and thioether moieties. Group R is preferably selected from, but not limited to, one of acrylamide, bromo, bromoacetamide, chloro, chloroacetamide, dithiopyridyl, hydrazide, N-hydroxysuccinimidyl ester, N-hydroxysulfo-succinimidyl ester, imidate ester, imidazolide, iodo, iodoacetamide, maleimide, amino and thiol moieties. Group Z is preferably an unbranched alkyl chain of the general formula (CH.sub.2)n, wherein n=1 to 6. Group Q is preferably selected from one of NHCO, CONH, NHCOCH.sub.2, CONHCH.sub.2, O, OCH.sub.2, S and SCH.sub.2 moieties.
    • 适于修饰生物活性物质的试剂,用于引入一种或多种苯基二硼酸(PDBA)部分以用于随后与不同(或相同)生物活性物质缀合的具有一个或多个通式的侧链化合物络合部分的生物活性物质 通式I,其中基团R是适于PDBA试剂与生物活性物质反应的反应性亲电或亲核部分。 Z组是选自饱和或不饱和链长度至多约0至6当量长度的间隔基,长度为约6至18当量长度的至少一个中间体酰胺或二硫化物部分的无支链饱和或不饱和链,以及 长度为约3至12碳当量的聚乙二醇链。 Q组是包括酰胺,醚和硫醚部分之一的连接。 基团R优选选自但不限于丙烯酰胺,溴代,溴乙酰胺,氯代,氯乙酰胺,二硫代吡啶基,酰肼,N-羟基琥珀酰亚胺酯,N-羟基磺基琥珀酰亚胺酯,亚氨酸酯,咪唑啉,碘,碘乙酰胺,马来酰亚胺 ,氨基和硫醇部分。 组Z优选为通式(CH 2)n的无支链烷基链,其中n = 1-6。组Q优选选自NHCO,CONH,NHCOCH2,CONHCH2,O,OCH2,S和SCH2部分之一。
    • 69. 发明授权
    • Phenylboronic acid complexing reagents derived from aminosalicylic acid
    • 衍生自氨基水杨酸的苯硼酸络合试剂
    • US6008406A
    • 1999-12-28
    • US805451
    • 1997-02-25
    • Mark L. Stolowitz
    • Mark L. Stolowitz
    • C07C229/38C07C233/49C07C233/51C07C237/12C07C237/22C07C255/13C07C259/10C07C271/22C07C281/02C07D207/44C07D207/452C07D207/46C07D213/71C07F5/02C07F5/04C07K5/02G01N33/543
    • C07D207/452C07C229/38C07C233/49C07C233/51C07C237/12C07C237/22C07C255/13C07C259/10C07C271/22C07C281/02C07D207/46C07D213/71C07F5/025C07K5/0207G01N33/54353
    • The present invention relates to novel class of phenylboronic acid complexing reagents useful for the preparation of bioconjugates, and the method of making and using such reagents. In the present invention, in the place of prior art Avidin-Biotin and Digoxigenin-anti-Digoxigenin systems, phenylboronic acid complexing reagents are utilized in conjunction with phenylboronic acid reagents (many of which are known in the prior art) to facilitate chemical conjugation without the use of intermediary biological macromolecules. Reagents suitable for the modification of a bioactive species for the purpose of incorporating a phenylboronic acid complexing moiety for subsequent conjugation to a different bioactive species having pendant phenylboronic acid moieties are of General Formula I or General Formula II. ##STR1## wherein group X is selected from either H, OH, NH.sub.2, NHCH.sub.3, NHOH and NHOCH.sub.3, wherein group Y is selected from either O, S and NH, and wherein group Z comprises a spacer which either separates the boronic acid complexing moiety from group R, as in General Formula I, or seperates two boronic acid complexing moieties, as in General Formula II. Group R is a reactive electrophilic or nucleophilic moiety suitable for reaction of the phenylboronic acid complexing reagent with a bioactive species.
    • 本发明涉及可用于制备生物缀合物的新一类苯基硼酸络合剂,以及制备和使用这些试剂的方法。 在本发明中,代替现有技术的抗生物素蛋白 - 生物素和地高辛 - 抗地高辛系统,苯硼酸络合试剂与苯硼酸试剂(许多已知在现有技术中)一起使用,以促进化学共轭而没有 使用中间生物大分子。 适于修饰生物活性物质的试剂为通式I或通式II,其用于将苯硼酸络合部分并入用于随后缀合至具有侧苯基硼酸部分的不同生物活性物质的目的。 其中基团X选自H,OH,NH 2,NHCH 3,NHOH和NHOCH 3,其中基团Y选自O,S和NH,并且其中基团Z包括将硼酸络合部分与基团R分离的间隔基 如通式I所示,或分离两个硼酸络合部分,如通式II所示。 基团R是适用于苯基硼酸络合试剂与生物活性物质反应的反应性亲电或亲核部分。